Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Abstract A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (Ctrough), ensuring similar target saturation and comparable efficacy/safety, to intravenous rituximab, but with simplified a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Nicolas Frey, Candice Jamois
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/96de8a1a1020405cb52160c9fa76dd90
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares